Summary
Abbott Laboratories reported solid performance for the first quarter of 2015, with total net sales from continuing operations reaching $4.9 billion, a 3.0% increase year-over-year. Despite a 7.0% negative impact from foreign exchange due to a stronger U.S. dollar, the company achieved a 10.0% increase in net sales when excluding currency fluctuations. This growth was bolstered by strong performance in key emerging markets and acquisitions completed in 2014, notably CFR Pharmaceuticals and Veropharm, which significantly expanded Abbott's branded generics pharmaceutical presence in Latin America and Russia, respectively. The company also completed the sale of its developed markets branded generics pharmaceuticals business and animal health business, reporting a substantial after-tax gain of $1.737 billion from these dispositions. This strategic move allowed Abbott to focus on its core businesses. The Established Pharmaceutical Products segment showed remarkable growth, driven by key emerging markets, and the Nutritional Products segment also demonstrated resilience, with international sales showing strong double-digit growth. While Vascular Products experienced a decline, partly due to pricing pressures, the overall financial health of Abbott remains robust, evidenced by improved gross profit margins and disciplined management of expenses and capital allocation, including significant share repurchases and a dividend increase.
Financial Highlights
54 data points| Revenue | $4.90B |
| Cost of Revenue | $2.08B |
| Gross Profit | $2.66B |
| SG&A Expenses | $1.74B |
| Operating Expenses | $4.29B |
| Operating Income | $610.00M |
| Interest Expense | $37.00M |
| Net Income | $2.29B |
| EPS (Basic) | $1.52 |
| EPS (Diluted) | $1.51 |
| Shares Outstanding (Basic) | 1.50B |
| Shares Outstanding (Diluted) | 1.52B |
Key Highlights
- 1Net sales from continuing operations grew 3.0% to $4.9 billion, with a 10.0% increase excluding foreign exchange headwinds.
- 2The company completed the sale of its developed markets branded generics pharmaceuticals and animal health businesses, resulting in a significant after-tax gain of $1.737 billion.
- 3Established Pharmaceutical Products sales surged 43.0% (excluding FX) driven by strong performance in key emerging markets, particularly India, Russia, and China.
- 4Acquisitions of CFR Pharmaceuticals and Veropharm in 2014 are contributing to growth, especially in Latin America and Russia.
- 5Gross profit margin improved to 54.3% from 49.5% in the prior year, attributed to margin initiatives and favorable comparisons.
- 6Abbott returned $1.25 billion to shareholders through share repurchases and increased its quarterly dividend by 9% to $0.24 per share.
- 7The company is managing foreign exchange headwinds effectively, with international sales showing a 13.6% increase when excluding currency impacts.